Citi analyst Joanne Wuensch raised the firm’s price target on Medtronic (MDT) to $101 from $99 and keeps a Buy rating on the shares. The firm adjusted targets in the medical technology space following the Q2 reports. Citi views the overall sector as healthy and opened “positive catalyst watches” on Edwards Lifesciences (EW) and Penumbra (PEN). The analyst also added iRhythm (IRTC) to its medtech top picks list, alongside Boston Scientific (BSX) and Edwards.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Early notable gainers among liquid option names on August 20th
- Medtronic price target raised to $95 from $94 at UBS
- Medtronic price target raised to $96 from $94 at Baird
- Medtronic price target raised to $98 from $97 at Bernstein
- Medtronic’s Strong Financial Performance and Positive Outlook Justify Buy Rating